Thursday, May 16, 2019
Q3 Medical Devices Limited ("Q3 Medical"), based in Dublin, Ireland, today announced the signing of a distribution agreement with Medtronic plc for ARCHIMEDES, the first biliary and pancreatic stent fully biodegradable designed as an alternative to traditional plastic stents.
Medtronic's Gastro-Intestinal Activity and Hepatology, part of the Minimally Invasive Therapies Group, and Q3 Medical have concluded an exclusive six-year agreement for the distribution of ARCHIMEDES biodegradable stents in Western Europe, the United States and Japan. with rights in other regions. Q3 Medical will continue to expand its presence in Southeast Asia, Latin America, Eastern Europe and the Middle East.
Generally, bile duct and pancreatic stents are made of plastic or metal, but the ARCHIMEDES stent is made of a combination of decomposable materials allowing different rates of dissolution depending on the patient's need. The use of degradable materials in a stent decreases the reoperations that are common with current stents and eliminates a removal procedure, which is almost always the case for plastic and metal stents. ARCHIMEDES has the CE mark.
Eric Mangiardi, President and Chief Executive Officer of Q3 Medical said, "We are very pleased to have partnered with a world leader in medical devices like Medtronic, and the signing of this agreement is a milestone. towards our goal of becoming the world leader in the development of biodegradable implants. "Mangiardi added:" The ARCHIMEDES promise is based on its potential to eliminate the second withdrawal procedure required for traditional plastic stents, which could reduce billions of expenditures of the global health system while improving patient care. "
About Q3 Medical Devices
Q3 Medical Devices Limited is a holding company based in Ireland that focuses on the acquisition of new medical device businesses with annual revenues of up to 10 million euros. The holding company, through its expanding activities in Winsen, Germany (QualiMed Innovative Medizinprodukte GmbH, AMG International GmbH), Shanghai, China (Q-San) and Charlotte, North Carolina (QualiMed-USA ), focuses on the development, manufacture and distribution of minimally invasive devices for the treatment of patients with peripheral and non-peripheral cardiovascular diseases.
The wholly-owned companies focus on developing and commercializing their core, micro-invasive, biodegradable and drug-release technologies worldwide. The Company's products are now sold in more than 50 countries worldwide through its OEM, private label and private label networks. Q3 Medical, through its wholly owned subsidiaries, focuses on three key vertical products in which it will compete: biodegradable implants, micro-invasive technologies and drug delivery platforms.
Q3 Medical Devices Limited was created by a global group of entrepreneurs, manufacturers, distributors, industry physicians and investors specializing in the development and acquisition of medical device companies. The company focuses on creating value by helping people.
For more information, please visit http://www.q3medical.com/ .
"CREATING VALUE BY HELPING PEOPLE" - "CREATING VALUE BY HELPING PEOPLE"
The text of the press release resulting from a translation must in no way be considered official. The only version of the release that is authentic is that of the release in its original language. The translation will always have to be confronted with the source text, which will make jurisprudence.
contacts
Eric Mangiardi
President & CEO
Q3 Medical Devices Limited
+353867827296 (Ireland)
emangiardi@q3medical.com
